Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Salubris (Chengdu) Biotech Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner and is located in 1 distinct art unit. This suggests a highly focused prosecution profile for the company's current filings. This indicates a highly concentrated prosecution footprint, where the company's current interactions with the patent office are limited to a single point of contact.
The busiest examiner for the portfolio is FONTAINHAS, AURORA M, who is responsible for the 1 pending office action. Since there is only 1 distinct examiner involved, the company's current interactions with the patent office are limited to a single point of contact. Practitioners should analyze the tendencies of this examiner to successfully navigate the pending office action. Because the portfolio is limited to 1 distinct art unit, the prosecution strategy can focus on the specific rules and trends of that group. Effectively managing the 1 pending office action is critical for the company's current intellectual property objectives in the biotechnology sector. The limited scope of the portfolio allows for a deep analysis of past decisions made within the 1 distinct art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FONTAINHAS, AURORA M | 1 | 37.8% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18333797 | HUMAN NEUREGULIN-1 (NRG-1) RECOMBINANT FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | FONTAINHAS, AURORA M | 12d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18333797 | HUMAN NEUREGULIN-1 (NRG-1) RECOMBINANT FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | FONTAINHAS, AURORA M | 12d |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18333797 | HUMAN NEUREGULIN-1 (NRG-1) RECOMBINANT FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | FONTAINHAS, AURORA M | 1675 | §103§112Other | Final Rejection | 12d | Pending | Jun 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSalubris (Chengdu) Biotech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Aurora M Fontainhas has the most, with 1 of Salubris (Chengdu) Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
